(Q33420634)

English

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Johanna C Bendell

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carla Kurkjian

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeffrey R Infante

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Todd M Bauer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Howard A Burris

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Anthony Greco

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kent C Shih

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dana S Thompson

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cassie M Lane

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lindsey H Finney

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suzanne F Jones

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

25 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

463-471

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0218-6

21 January 2018

Identifiers

10.1007/S10637-015-0218-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33420634&oldid=2195345673"